No connection

Search Results

CARL vs MASS

CARL
Carlsmed, Inc.
NEUTRAL
Price
$9.74
Market Cap
$260.4M
Sector
Healthcare
AI Confidence
80%
MASS
908 Devices Inc.
BEARISH
Price
$7.20
Market Cap
$269.1M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
CARL
--
MASS
--
Forward P/E
CARL
-6.56
MASS
-24.41
P/B Ratio
CARL
2.62
MASS
1.82
P/S Ratio
CARL
5.15
MASS
4.79
EV/EBITDA
CARL
-5.5
MASS
-7.75

Profitability

Gross Margin
CARL
75.31%
MASS
51.11%
Operating Margin
CARL
-61.44%
MASS
-17.3%
Profit Margin
CARL
-58.67%
MASS
34.68%
ROE
CARL
-47.62%
MASS
-25.77%
ROA
CARL
-21.0%
MASS
-9.02%

Growth

Revenue Growth
CARL
61.2%
MASS
-7.7%
Earnings Growth
CARL
--
MASS
--

Financial Health

Debt/Equity
CARL
0.18
MASS
0.03
Current Ratio
CARL
8.87
MASS
4.24
Quick Ratio
CARL
8.48
MASS
3.65

Dividends

Dividend Yield
CARL
--
MASS
--
Payout Ratio
CARL
0.0%
MASS
0.0%

AI Verdict

CARL NEUTRAL

CARL shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Mixed signals with both opportunities and risks present.

Strengths
Strong revenue growth of 61.2%
Low debt with D/E ratio of 0.18
Risks
Low profit margin of -58.7%
Weak financial trend (Piotroski F-Score: 1/9)
Weak ROE of -47.6%
MASS BEARISH

The company exhibits severe financial fragility, highlighted by a Piotroski F-Score of 1/9, indicating a critical lack of fundamental strength. While the balance sheet shows strong liquidity (Current Ratio 4.24) and minimal debt (Debt/Equity 0.03), these are offset by negative revenue growth (-7.70% YoY) and persistent operating losses. Insider sentiment is strongly bearish, with the CEO, CFO, and Directors selling shares amidst a long-term price collapse of 85.9% over five years. The disconnect between the high reported profit margin and the negative operating margin suggests non-operational gains rather than a sustainable business model.

Strengths
Strong short-term liquidity with a Current Ratio of 4.24
Very low leverage with a Debt/Equity ratio of 0.03
Healthy Gross Margins at 51.11%
Risks
Critical financial health failure as indicated by Piotroski F-Score (1/9)
Negative organic growth with YoY revenue declining by 7.70%
Negative operating margins (-17.30%) indicating an unsustainable cost structure

Compare Another Pair

CARL vs MASS: Head-to-Head Comparison

This page compares Carlsmed, Inc. (CARL) and 908 Devices Inc. (MASS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile